Bronchoalveolar lavage for the diagnosis and treatment of pneumonia associated with transport in Thoroughbred racehorses.

The research sought to determine if bronchoalveolar lavage (BAL) could improve the prognosis of pneumonia in traveling Thoroughbred racehorses by reducing both bacterial levels and excessive numbers of neutrophils in the lung. The study demonstrated that horses treated with BAL had higher recovery rates and shorter antibiotic therapies.

Introduction to the Study

• The purpose of this study was to assess the effectiveness of bronchoalveolar lavage (BAL) as a treatment method for pneumonia in Thoroughbred racehorses that have recently undergone long-distance travel.
• The researchers hypothesized that the early administration of BAL would improve the prognosis of the affected racehorses by reducing the numbers of disease-causing bacteria and excessive neutrophils in the lung. Neutrophils are a type of white blood cell that can signal inflammation.

Methodology

• The study was performed on a total of 36 racehorses that fell ill within 24 hours following long-distance travel of roughly 1,200 to 1,600 km by road.
• For comparative purposes, the outcomes of these horses were juxtaposed against those of 42 horses previously treated for transport-associated pneumonia without BAL.
• The volume of BAL fluid administered over the course of hospitalization varied between individual horses, ranging from 700 to 3,700 ml. Similarly, the duration of antibiotic treatments also varied, ranging from 5 to 40 days.

Findings and Observations

• Overall, the results observed following lavages were favourable, with no side effects noted. None of the treated horses required thoracic drainage.
• Horses treated with BAL required a shorter period of antibiotic therapy compared to those not treated with BAL.
• All of the BAL-treated horses recovered, and approximately 78% returned to racing. The rest did not race due to issues unrelated to their treatment, such as lameness or other considerations.
• The findings indicate that the use of BAL for early treatment of pneumonia in racehorses could potentially yield better outcomes, increasing both recovery rates and the likelihood of a return to racing.